EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Stress testing the Centiloid: Precision and variability of PET quantification of amyloid pathology

Mahnaz Shekari iD, David Vállez García iD, Lyduine E Collij iD, Daniele Altomare iD, Fiona Heeman iD, Hugh Pemberton iD, Núria Roé Vellvé, Santiago Bullich, Christopher Buckley, Andrew Stephens, Gill Farrar iD, Giovanni Frisoni iD und 4 weitere

Alzheimer's & Dementia · 2024-08 · 20 (8) · 5102-5113

DOI: 10.1002/alz.13883 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 04.07.2024. Verfasst von Mahnaz Shekari und 15 weiteren Autor:innen. Beteiligte Einrichtung: Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain. Hauptthemen laut MEDLINE: Alzheimer Disease, Positron-Emission Tomography, Brain. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Alzheimer Immunotherapy Research & Development, LLC, Innovative Medicines Initiative 2 Joint Undertaking, GE Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Assessing the potential sources of bias and variability of the Centiloid (CL) scale is fundamental for its appropriate clinical application. METHODS We included 533 participants from AMYloid imaging to Prevent Alzheimer's Disease (AMYPAD DPMS) and Alzheimer's Disease Neuroimaging Initiative (ADNI) cohorts. Thirty‐two CL pipelines were created using different combinations of reference region (RR), RR and target types, and quantification spaces. Generalized estimating equations stratified by amyloid positivity were used to assess the impact of the quantification pipeline, radiotracer, age, brain atrophy, and harmonization status on CL. RESULTS RR selection and RR type impact CL the most, particularly in amyloid‐negative individuals. The standard CL pipeline with the whole cerebellum as RR is robust against brain atrophy and differences in image resolution, with 95% confidence intervals below ± 3.95 CL for amyloid beta positivity cutoffs (CL < 24). DISCUSSION The standard CL pipeline is recommended for most scenarios. Confidence intervals should be considered when operationalizing CL cutoffs in clinical and research settings. Highlights We developed a framework for evaluating Centiloid (CL) variability to different factors. Reference region selection and delineation had the highest impact on CL values. Whole cerebellum (WCB) and whole cerebellum plus brainstem (WCB+BSTM) as reference regions yielded consistent results across tracers. The standard CL pipeline is robust against atrophy and image resolution variation. Estimated within‐ and between‐pipeline variability (95% confidence interval) in absolute CL units.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseasePositron-Emission TomographyBrainHumansAgedFemaleMaleAtrophyAmyloidNeuroimagingAged, 80 and overAmyloid beta-Peptides

Stichwörter der Autor:innen

Alzheimer's diseaseageamyloid PET accuracybiomarker validationbrain atrophyclinical applicationsclinical trialscontext of usediagnosisdisease‐modifying therapiesimage harmonizationradiotracerswhite matter

Substanzen

AmyloidAmyloid beta-Peptides

Autor:innen und Institutionen

  • Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
  • IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Universitat Pompeu Fabra, Barcelona, Spain.
  • Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
  • Clinical Memory Research Unit, Clinical Sciences Malmö, Lund University, Malmö, Sweden.
  • Memory Center, Department of Rehabilitation and Geriatrics, University Hospitals and University of Geneva, Genève, Switzerland.

ORCID-Profile: Mahnaz Shekari, David Vállez García, Lyduine E Collij, Daniele Altomare, Fiona Heeman, Hugh Pemberton, Gill Farrar, Giovanni Frisoni, William E Klunk, Frederik Barkhof, Juan Domingo Gispert

Förderung

  • Janssen Alzheimer Immunotherapy Research & Development, LLC
  • Innovative Medicines Initiative 2 Joint Undertaking
  • GE Healthcare
  • Transition Therapeutics
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Eisai Inc.
  • Department of Defense

Zitieren

APA

Shekari, M., Vállez García, D., Collij, L. E., Altomare, D., Heeman, F., Pemberton, H., Roé Vellvé, N., Bullich, S., Buckley, C., Stephens, A., Farrar, G., Frisoni, G., Klunk, W. E., Barkhof, F., Gispert, J. D., & ADNI and the AMYPAD consortium (2024). Stress testing the Centiloid: Precision and variability of PET quantification of amyloid pathology. Alzheimer's & Dementia, 20(8), 5102-5113. https://doi.org/10.1002/alz.13883

Vancouver

Shekari M, Vállez García D, Collij LE, Altomare D, Heeman F, Pemberton H, et al. Stress testing the Centiloid: Precision and variability of PET quantification of amyloid pathology. Alzheimer's & Dementia. 2024;20(8):5102-5113. doi:10.1002/alz.13883

BibTeX
@article{Shekari2024,
  author = {Shekari, Mahnaz and Vállez García, David and Collij, Lyduine E and Altomare, Daniele and Heeman, Fiona and Pemberton, Hugh and Roé Vellvé, Núria and Bullich, Santiago and Buckley, Christopher and Stephens, Andrew and Farrar, Gill and Frisoni, Giovanni and Klunk, William E and Barkhof, Frederik and Gispert, Juan Domingo and ADNI and the AMYPAD consortium, ADNI and the AMYPAD consortium},
  title = {Stress testing the Centiloid: Precision and variability of PET quantification of amyloid pathology},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  volume = {20},
  number = {8},
  pages = {5102--5113},
  doi = {10.1002/alz.13883}
}
Kostenlos starten →